The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Is this the incentive that will move the share price
Mr Nunn’s potential pay packet tops the £8.3m that his predecessor, António Horta-Osório, could have achieved under the last pay policy approved by shareholders in 2020.
Chief Financial Officer William Chalmers is in line for a maximum pay rise to £6.3m from £4.7m, thanks in part to a rise in his potential bonus, which could now be worth 140% of his salary, up from 100%.
Both estimates are based on Lloyds’ share price rising 50%.
The Group's total borrowings at March 31, 2023 were €19,767 million
Net debt (total borrowings less cash, cash equivalents and current interest-bearing deposits) was €8,398 million at March 31, 2023, a reduction of €1,987 million since December 31, 2022, mainly due to the increase in cash outlined above.
I have just come across this company and cannot make any sense of the share price. Why has there been wild fluctuations in the SP over 12 months?
Taking the following figures into account. IF we factor in a conservative figured of 10% uptake amongst these sufferers and a profit €5 per pack ( again conservative) in the rollout period .Then potentially going forward, we could see 300 million on the Horizon ( with FDA approval) which could very well be achievable returns
The worldwide prevalence of erectile dysfunction is expected to increase to 322 million men by 2025. (International Journal of Impotence Research, 2000)
ED affects about 30 million men in the United States. (Current Opinion in Nephrology and Hypertension, 2012)
The margins for a product that retails over 20 pounds will be significant. The unit uptake in the first few months from publicity alone will be huge. The % of ED sufferers will no doubt be curious and many will try the product out when it comes to their attention. It then comes down to repeat business on the back of a user experience . Moving forward 2023 as we know is a rollout year. The SP “Should” keep pace with publicity. Think how many potential investors globally are unaware of this product. As this hits the news there will be a lot of small investors like ourselves mulling over the potential of this product, including those that begin to use it regularly
There are 2200 boots pharmacies in the Uk . If you calculate a conservative 10 packs sold per month from each, you get to a very interesting number, both in packs and revenue. Then if you factor in a gradual rollout worldwide with the kind of publicity we have seen just in the UK . This will be very interesting 2023 ride!!!!
The following reports hopefully will impact the IAG share Price
For their last quarter, American Airlines (AAL) reported earnings of $1.17 per share, beating the Zacks Consensus Estimate of $1.14 per share. This reflects a positive earnings surprise of 2.63%. Look out for AAL's next earnings release expected on April 20, 2023. For the next earning release, we expect the company to report earnings of $0.03 per share, reflecting a year-over-year increase of 101.29%.
April 18th United Airlines is expected to post quarterly loss of $0.61 per share in its upcoming report, which represents a year-over-year change of +85.6%.
Revenues are expected to be $11.42 billion, up 50.9% from the year-ago quarter.
Wizz air 2022 loss 642 million debt 3.11 Billion SP 2728
Tui 2022 loss 212 million debt 3.4billion SP 575
Easyjet 2022 loss 169 million debt 670 million SP 495
Ryanair 2022 loss 241 million debt 1.45 billion SP1276
Jet 2 2022 loss 315 million debt 991 million SP 1291
IAG 2022 PROFIT 431 million debt 9.4 billion SP 150
comparing the fundamentals across the European Airlines
Wizz air 2022 loss 642 million
Tui 2022 loss 212 million
Easyjet 2022 loss 169 million
Ryanair 2022 loss 241 million
Jet 2 2022 loss 315 million
IAG 2022 PROFIT 431 million
I think we are in a good place going forward . If you play the waiting game, IAG figures certainly suggest a positive sentiment, when you look at the industry as a whole. Yes this is going to take time. But if they keep reinvesting and paying down debt then the future looks bright
DYOR
Below is the full presentation, Interesting that they say at the end, they have enough cash to go beyond the FDA approval and that they will be generating a cash positve situation from the 2nd Qtr
https://www.futuramedical.com/investor-centre/videos-and-webcasts/webcasts/
Operating loss for the first quarter €731 million (2021 restated1: operating loss €1,077 million), and operating loss before exceptional items €754 million (2021 restated1: operating loss before exceptional items €1,144 million)
· Loss after tax and exceptional items for the first quarter €787 million (2021 restated1: loss €1,074 million) and loss after tax before exceptional items €810 million (2021 restated1: loss €1,131 million)
· Cash was €8,184 million at March 31, 2022, up €241 million on December 31, 2021, with significantly positive working capital, driven by bookings for the remainder of the year
Sp at 151 as of May 2022
May 2023 Figures likely to come in a Tad better !!!!!!!!!
I will not go into to much detail, but when i was selling Viagra for Pfizer as a medical rep,I was confronted with a mixed reception from healthcare professionals. Many were naturally sceptical ,whilst others were widely exited about offering this unique treatment to their patients. A Per-launch/post launch frenzy of articles unfolded, country by country about what this breakthrough offered. But in all the years ,the one question that many HCP asked was when was the topical treatment coming. And as we all know, in recent weeks /months only now has that alternative been forthcoming. If either Pfizer or Lilly had that range of treatments , then the landscape for ED treatment would be very different today. Historically a high percentage of patients ,do not like taking oral medication. Topical treatments always win out. From my perspective I believe that this new treatment will unfold exponentially. As we know Futura is a Minnow in comparison to the giants of the pharmaceutical industry, and they have limited resources when it comes to marketing. They will no doubt focus those resources to get the maximum return on exposure. But Gps and ED specialists will eventually point ED suffers in the direction of a topical treatment. And yes like oral Ed treatments not all patients respond. But until you try as a sufferer you will not know if this product works for you. The ED market is and always will be a huge cash cow for those in the market. There will always be millions who suffer from this disease and the potential rewards go hand in hand. Not if, but when this product goes viral around the World, the big players will take notice. They cannot allow an ED treatment (outside their portfolios ) to start eating into their market share. Also any big player who steps in, and Markets this for themselves will suddenly be at the forefront of ED treatments. Now that the product has been launched, the media in those countries will raise the noise levels . Time and patience is what is needed from shareholders. Viagra is what launched Pfizer share price all those years ago. Futura is at the beginning of that journey and we will be privileged to see it unfold in the coming months. There will be setbacks. The other companies may try to rubbish the product, in an effort to sow doubt about its efficacy . This is typical of the industry. But bad news can also be good news in upping the sound bits. There is a long and twisting road ahead, but this unique product will eventually pull through
I agree with all the comments. However the one thing that remains uncertain going forward, is the size of profits IAG could make. When profits start to become clearer I think IAG will face a dilemma. They will have to put money into the pension pots, and if they have anything substantial left over, they may choose to pay down some debt. This “COULD” provide the stimulus needed to lift the SP. There is still a lot of unknowns ahead. The next set of financial results should give us a strong heads up on that direction
DYOR